# A Study of Emapalumab for Pediatric Aplastic Anemia

> **NCT06430788** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 35 (estimated)

## Conditions studied

- Aplastic Anemia
- Cytopenia
- Hypocellular Marrow

## Interventions

- **BIOLOGICAL:** Emapalumab

## Key facts

- **NCT ID:** NCT06430788
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2029-05-21
- **Final completion:** 2029-05-21
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06430788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06430788, "A Study of Emapalumab for Pediatric Aplastic Anemia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06430788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*